References
- Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
- Baselga J, Averbuch S D. ZD1839 (‘Iressa’) as an anticancer agent. Drugs 2000; 60(Suppl 1)33–40
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon N B, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90: 4947–52
- Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7
- Druker B, Sawyers C L, Kataqian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–42
- Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Oncol 2001; 6: 1–5
- Miettinen M, Lasota J. Gastrointestinal stromal tumors -definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12
- De Matteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann SUrg 2000; 231: 51–8
- Broudy V C. Stem cell factor and hematopoiesis. Blood 1997; 90: 1345–64
- Joensuu H, Roberts P, Sarlomo-Rikala M, Anderson L C, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6
- Blanke C D, von Mehren M, Joensuu H, Roberts P J, Eisenberg B, Heinrich M, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117) (Abstract). Proc Am Soc Clin Oncol 2001; 20: 1a
- Van Oosterom A T, Judson I, Verweij J, Di Paola E, van Glabbeke M, Dimitrijevic S, et al. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study (Abstract). Proc Am Soc Clin Oncol 2001; 20: 1a
- Van den Abbeele A D. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) (Abstract). Proc Am Soc Clin Oncol 2001; 20: 362a